Welcome to our dedicated page for CIBUS news (Ticker: CBUS), a resource for investors and traders seeking the latest updates and insights on CIBUS stock.
Cibus, Inc. (Nasdaq: CBUS) is an agricultural technology company that develops and licenses gene-edited plant traits to seed companies, with a focus on productivity traits for major row crops. The CBUS news page on Stock Titan aggregates company announcements, business updates, regulatory milestones, and collaboration news directly relevant to Cibus’ trait development and commercialization plans.
In its news releases, Cibus highlights progress in rice herbicide-tolerance traits HT1 and HT3, including material transfer agreements and a non-binding letter of intent with organizations and companies in Latin America to introduce these traits into elite rice germplasm and to prepare for commercialization in key rice-producing markets. The company also reports on collaborations aimed at bringing its gene editing technologies to India’s rice seed industry through strategic advisory partnerships.
News coverage for CBUS also includes updates on canola trait programs, such as positive field trial results for its HT2 herbicide-tolerance trait in North America and field trials for pod shatter reduction and disease resistance traits in winter oilseed rape. Additional items describe Cibus’ sustainable ingredients program, where the company has completed pre-commercial pilot runs for certain biofragrance products and received initial payments associated with commercialization efforts.
Investors and observers can use the CBUS news feed to follow Cibus’ participation in regulatory developments around gene editing in regions such as the European Union, the United Kingdom, North America and Ecuador, as well as corporate governance changes, board appointments, workforce adjustments and strategic focus updates. Regular visits to this page provide a consolidated view of how Cibus’ trait pipeline, partnerships and regulatory environment are evolving over time.
Cibus (NASDAQ: CBUS) has successfully completed the FDA's Plant Biotechnology Consultation Program for its altered lignin alfalfa trait, developed in partnership with S&W Seed Company. The FDA confirmed it has no further questions regarding the use of this gene-edited alfalfa in food or feed applications.
The altered lignin alfalfa offers two key benefits: potential improved digestibility for livestock and greater harvest timing flexibility for farmers. S&W Seed Company plans to commercialize two initial variety offerings - a fall dormancy five variety and a fall dormancy seven variety - marking the first commercial gene-edited alfalfa varieties in the United States.
Cibus (NASDAQ: CBUS), an agricultural biotechnology company specializing in proprietary gene editing technologies for seed trait development, has made available a replay of its participation in the BofA Securities 2025 AgTech Virtual Conference. During the fireside chat, Co-Founder, President and Interim CEO Peter Beetham discussed with BofA analyst Stephen Byrne three key areas: the company's unique gene editing platform, progress in their productivity trait pipeline toward commercial goals, and the impact of recent regulatory changes supporting agricultural innovation globally. The webcast recording can be accessed through Cibus's investor relations website.
Cibus (NASDAQ: CBUS), an agricultural biotechnology company specializing in proprietary gene editing technologies for seed trait development, announced its participation in the AGP Annual Virtual Healthcare Company Showcase. Peter Beetham, Co-Founder, President, and Interim CEO, will present on May 21, 2025, at 4:40 p.m. ET.
The presentation will cover three main areas: the company's progress in advancing its gene-editing technology platform, recent regulatory developments supporting agricultural innovation, and Cibus' commercialization strategy for its productivity trait pipeline.
Ecuador's Ministry of Agriculture and Livestock has determined that Cibus' (CBUS) herbicide tolerance Rice traits (HT1 and HT3) are equivalent to conventional breeding methods. This regulatory approval means these traits will be subject to standard seed regulations rather than strict GMO restrictions in Ecuador.
The traits, developed using Cibus' Rapid Trait Development System™ (RTDS®) technology, create targeted genetic changes without introducing foreign genetic material. Cibus plans to commercialize these traits in Latin American markets through a partnership with Interoc, focusing on providing improved weed management solutions for rice growers.